COVID-19 vaccine safety in pregnant and non-pregnant women

This population-based, exposure-matched cohort study assessed the incidence of medically attended adverse events following COVID-19 vaccination and SARS-CoV-2 infection in over one million pregnant and non-pregnant women of reproductive age in the United States between December 2020 and September 2022 Data were extracted from national insurance claims databases, which included vaccination records, laboratory-confirmed COVID-19 diagnoses, and a wide spectrum of outcomes across immunologic, neurologic, thromboembolic, cerebrovascular, cardiovascular, respiratory, thrombocytopenic, and coagulation systems. Matching was conducted on age, insurance type, preexisting comorbidities, and, for pregnant individuals, gestational age and timing of pregnancy, ensuring strong comparability between groups Adverse event rates following vaccination were very low in both pregnant and non-pregnant women, with no statistically significant difference in overall incidence (pregnant: adjusted odds ratio [aOR] 1.04, 95% CI 0.96–1.13; non-pregnant: aOR 1.19, 95% CI 1.11–1.28). Rare neurological complications such as generalized convulsions and Guillain-Barré syndrome were observed, though with marginally higher—but still minimal—odds in...